25C-NBOMe Stats & Data
COc1ccccc1CNCCc1cc(OC)c(Cl)cc1OCFJFPOGCVVLUYAQ-UHFFFAOYSA-NHistory & Culture
25C-NBOMe was discovered in 2003 by Ralf Heim at the Free University of Berlin. The compound was subsequently investigated by a research team at Purdue University led by David Nichols, and was first formally described in the scientific literature by Anders Ettrup and colleagues in 2010. Research interest in 25C-NBOMe has centered on its potential applications in neuroimaging. Scientists have studied its carbon-11 radiolabelled form as a ligand for mapping the distribution of serotonin 5-HT2A receptors in the brain using positron emission tomography (PET). The compound had virtually no history of recreational human use prior to 2010, when it first emerged on the online research chemical market. Its exceptional potency—approximately sixteen times that of its parent compound 2C-C—allows effective doses to fit onto blotter paper, similar to LSD. This characteristic has led to instances where 25C-NBOMe has been found on blotter mimics sold as LSD, contributing to safety concerns and prompting regulatory responses across numerous jurisdictions beginning in 2011.
Subjective Effects
Physical
The physical effects of 25C-NBOMe can be broken down into several components which progressively intensify proportional to dosage.
- Stimulation and Sedation: In terms of its effects on the subject's physical energy levels, 25C-NBOMe is considered to be energetic and well as sedating, leaving the subject in a state of equilibrium between being stationary and moving. The physical stimulation manifested by this substance can be described as similar to 2C-B, and is commonly experienced as simultaneously easygoing and physically difficult, sometimes presenting overstimulation which results in bodily shakes and teeth grinding. The levels of stimulation can be considered less intense than 25I-NBOMe and the sedation can be considered slightly less intense than other psychedelics such as Psilocin and 2C-C.
- Sublingual numbing: Assuming the substance has been taken sublingually, the very first physical effect which a person will notice immediately after sublingual absorption is a strong, unpleasant metallic chemical taste. This is accompanied by a very obvious feeling of general numbness of the tongue and mouth which can stay for up to an hour after the blotter paper has been consumed. This is the key difference when it comes to determining whether your blotter paper contains LSD or one of the NBOMe series.
- Temperature regulation loss
- Spontaneous tactile sensations: The body high itself can be described as a generally mild, all-encompassing, soft but euphoric tingling sensation. This tingling sensation is also accompanied by spontaneous rushes of euphoria that become longer and more drawn out proportional to the dosage consumed.
- Perception of decreased weight: In terms of the body's perceived weight, this substance consistently leaves people feeling extremely light, often to the point of total weightlessness.
- Tactile hallucinations
- Changes in gravity: Compared to classic tryptamines, this effect is considerably less intense than what is commonly experienced with DMT and Psilocin.
- Nausea: As the tripper begins to come up, nausea is not uncommon and can sometimes result in initial vomiting, but passes once this has either happened or the trip begins to fully set in. In comparison to other psychedelics such as psilocin, LSD, 2C-E and 2C-I, this could actually be very considered very mild in its intensity.
- Vasoconstriction
- Increased heart rate
- Pupil dilation
- Wakefulness
- Increased blood pressure
Cognitive
The cognitive effects of 25C-NBOMe are described by many as remarkably light and underwhelming in comparison to more traditional psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages, however, mild to overwhelming cognitive alterations become present; this dosage seems to be lower in proportion to physical effects when compared to 25I-NBOMe.
- Analysis enhancement: This component is consistently manifested only in the context of a non-social setting in which the user is alone and is introspection dominant.
- Empathy, love and sociability enhancement: The entactogenic effects range from mild to powerful, but are inconsistently manifested. Entactogenic effects for people who try this substance usually become prominent in the presence of others. These feelings of increased sociability, love and empathy do not seem to be quite as strong or profound as those found within other entactogens (such as MDMA, 2C-B and AMT)
- Thought acceleration
- Time distortion
- Immersion enhancement
- Novelty enhancement
- Conceptual thinking
- Thought connectivity
- Current mind state enhancement
- Personal bias suppression
- Memory suppression
- Ego death
Sensory
- Enhancements
- Distortions
- Hallucinations
- Drifting: (Melting, flowing, breathing and morphing) - In comparison to other psychedelics this effect can be described as highly detailed, slow and smooth in motion, static in their appearance and unrealistic/cartoon-like in style.
- Tracers
- After images
- Symmetrical texture repetition
- Colour shifting
- Scenery slicing
- Transformations
- Environmental cubism
- Diffraction
25C-NBOMe presents a full and complete array of possible visual enhancements.
- Visual acuity enhancement
- Colour enhancement
- Pattern recognition enhancement
25C-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently. However, level 4 - 5 hallucinatory breakthroughs are reported but very uncommon and inconsistent in comparison to other more commonly used psychedelics such as psilocin, 2C-E and DMT. This can be considered as on par with and identical in behaviour to that of LSD and 25I-NBOMe.
- Transformations
- Internal hallucinations: (Autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) These are more common within dark environments and can be described as internal in their manifestation, lucid in believability, interactive in style and almost exclusively of religious, spiritual, mystical or a transcendental nature in their overall theme.
- External hallucinations: (Autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots). These are often manifesting as rapidly moving, interactive solid and typically asymmetrical matter or physical beings reflecting imagined concepts. They are more common in bright environments and can be described as external in their manifestation, equally lucid and delirious in believability, interactive in style, autonomous in interaction, and almost exclusively alien, mystical, or a transcendental nature in their overall theme.
Forked from Subjective Effect Documentation by Josie Kins, September 2015. Via dose.wiki (CC0).
Toxicity
PsychonautWiki25C-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The LD50 has not yet been determined although it can be fatal at heavy dosages. It is advised that due to 25C-NBOMe's extreme potency it should not be insufflated (snorted) as this method of administration has been attributed to several fatal overdoses due to improper dosing. It is strongly recommended that one use harm reduction practices when using this substance.
Addiction & dependence
25C-NBOMe is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating. Tolerance to the effects of 25C-NBOMe is built almost immediately after ingestion.
Effect Profile
Curated + 136 ReportsStrong visuals, headspace, auditory effects, and body load
Duration Timeline
BluelightCommunity Effects
TripSitTolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Acute tolerance: develops within a single session — the reset numbers above apply after sustained heavy use, not after one binge. Within-session tachyphylaxis usually resets largely overnight.
Cross-Tolerances
Demographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
Erowid + BluelightEffects aggregated from 136 experience reports (113 Erowid + 23 Bluelight)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 39
Adverse Effects 46
Dose-Response Correlation
How effect frequency changes across dose levels
View data table
| Effect | Common (n=25) | Heavy (n=14) |
|---|---|---|
| Visual Distortions | 100.0% | 92.9% |
| Anxiety | 68.0% | 92.9% |
| Color Enhancement | 76.0% | 71.4% |
| Euphoria | 72.0% | 50.0% |
| Music Enhancement | 60.0% | 64.3% |
| Confusion | 40.0% | 50.0% |
| Tactile Enhancement | 24.0% | 50.0% |
| Introspection | 36.0% | 42.9% |
| Empathy | 32.0% | 42.9% |
| Auditory Effects | 32.0% | 42.9% |
| Focus Enhancement | 32.0% | 42.9% |
| Nausea | 40.0% | 35.7% |
| Dissociation | 36.0% | 14.3% |
| Body High | 32.0% | 35.7% |
| Stimulation | 32.0% | 35.7% |
Subjective Effect Ontology
Experience ReportsStructured effect tags extracted from 136 Erowid & Bluelight experience reports using a controlled vocabulary of 220+ canonical effects across 15 domains.
Visual
Dose–Effect Mapping
Experience ReportsHow reported effects shift across dose tiers, based on 113 experience reports.
Limited tier coverage — most reports fall within the Common / Heavy range. Effects at other dose levels may not be represented.
| Effect | Common (n=25) | Heavy (n=14) | |
|---|---|---|---|
| visual distortions | → | ||
| anxiety | ↑ | ||
| color enhancement | → | ||
| euphoria | ↓ | ||
| music enhancement | → | ||
| confusion | ↑ | ||
| tactile enhancement | ↑ | ||
| introspection | ↑ | ||
| empathy | ↑ | ||
| auditory effects | ↑ | ||
| focus enhancement | ↑ | ||
| nausea | → | ||
| dissociation | ↓ | ||
| body high | → | ||
| stimulation | → | ||
| closed-eye visuals | ↑ | ||
| open-eye visuals | — | → | |
| sedation | ↑ | ||
| hospital | — | → | |
| ego dissolution | → |
Showing top 20 of 33 effects
Risk Escalation
Sentiment AnalysisAverage frequency of positive vs adverse effects across dose tiers
View effect breakdown
Adverse Effects
| Effect | Common (n=25) | Heavy (n=14) | Change |
|---|---|---|---|
| Anxiety | +36% | ||
| Confusion | +25% | ||
| Nausea | -10% | ||
| Thought Loops | +33% | ||
| Muscle Tension | +33% | ||
| Memory Suppression | +167% | ||
| Jaw Clenching | +167% | ||
| Sweating | — | 0% | |
| Motor Impairment | — | 0% | |
| Seizure | — | 0% | |
| Headache | — | 0% | |
| Increased Heart Rate | — | 0% | |
| Pupil Dilation | — | 0% |
Positive Effects
| Effect | Common (n=25) | Heavy (n=14) | Change |
|---|---|---|---|
| Color Enhancement | -6% | ||
| Euphoria | -30% | ||
| Music Enhancement | 7% | ||
| Tactile Enhancement | +108% | ||
| Introspection | +19% | ||
| Empathy | +34% | ||
| Focus Enhancement | +34% | ||
| Body High | +11% | ||
| Stimulation | +11% | ||
| Pain Relief | — | 0% | |
| Creativity Enhancement | — | 0% |
Dosage Distribution
Dose distribution from experience reports
Insufflated
Sublingual
Real-World Dose Distribution
62K DosesFrom 125 individual dose entries
Sublingual (n=48)
Insufflated (n=21)
Oral (n=10)
Common Combinations
Most co-occurring substances in experience reports
Form / Preparation
Most common forms and preparations reported
Body-Weight Dosing
Dose relative to body weight from reports with weight data
Oral
Insufflated
Sublingual
Unknown
Redose Patterns
Redosing behavior across 100 reports
Legal Status
| Country | Status | Notes |
|---|---|---|
| Austria | Illegal (SMG) | Prohibited since June 26, 2019 under the Suchtmittelgesetz (SMG). Possession, production, and sale are illegal. |
| Brazil | Controlled | Listed on Portaria SVS/MS nº 344 as of February 18, 2014. The entire NBOMe series became controlled at this time, including 25I-, 25C-, 25D-, 25B-, 25E-, 25N-, 25P-, 25T2-, 25T7-, and 25H-NBOMe. |
| Canada | Schedule III (CDSA) | Controlled as of October 31, 2016 as a derivative of 2,5-dimethoxyphenethylamine under the Controlled Drugs and Substances Act. |
| China | Controlled | Classified as a controlled substance since October 2015. |
| Czech Republic | Banned | Prohibited under national controlled substances legislation. |
| Germany | Anlage I BtMG | Listed in Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since December 13, 2014. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without a license are prohibited. |
| Israel | Controlled | The NBOMe series became controlled in May 2013. |
| Italy | Schedule I | Classified as a Schedule I controlled substance. Possession, distribution, and manufacture are illegal. |
| Japan | Narcotic | Designated as a narcotic drug effective November 1, 2015. |
| Latvia | Schedule I | Classified as a Schedule I controlled substance. |
| New Zealand | Class C analogue | Considered substantially similar in chemical structure to the controlled hallucinogen DOB and therefore treated as a Class C controlled drug analogue. Withdrawn from sale in early 2012 following a statement by Associate Health Minister Peter Dunne. |
| Russia | Controlled | The entire NBOMe series became controlled in October 2011, making Russia the first country to regulate this class of substances. |
| Sweden | Schedule I | Added to Schedule I (substances without medical use) as of August 1, 2013, published in Medical Products Agency regulation LVFS 2013:15. |
| Switzerland | Controlled (Verzeichnis D) | Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics legislation. |
| Turkey | Illegal | Classified as a controlled drug. Possession, production, supply, and import are prohibited. |
| United Kingdom | Class A | Controlled as a Class A substance since June 2014 under the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971. Previously subject to a temporary class drug order from June 10, 2013. |
| United States | Schedule I | Emergency scheduled by the DEA on November 15, 2013, along with 25B-NBOMe and 25I-NBOMe under the Controlled Substances Act. The temporary scheduling was extended in November 2015. Several states including Arkansas, Georgia, and Louisiana added it to their Schedule I lists prior to federal action. Scheduling also makes other NBOMe compounds probable Controlled Substance Analogues when intended for human consumption. |